Shubham Pant, Professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at MD Anderson Cancer Center, shared on LinkedIn:
“For nearly 40 years, KRAS was considered ‘undruggable.’ I sat down with my colleague David S. Hong, UT MD Anderson to talk about how that’s changing, and fast!!
A few things that still amaze me about this moment in pancreatic cancer research:
- KRAS drives almost 90% of pancreatic cancers. It’s stuck in the “on” position, like a light switch you can’t flip off. For decades, we didn’t have a way to reach it.
- RASolute 302 changed that. Patients on daraxonrasib, a pan-RAS inhibitor taken as a daily pill, lived a median of 13.2 months vs. 6.7 months on standard chemotherapy after one prior line of treatment. In a disease where past “wins” have meant a few extra weeks, doubling survival is hard to overstate.
- We’re not stopping there. Multiple trials are now underway targeting pan-RAS as well as allele-specific inhibitors, moving these therapies earlier in treatment, into the adjuvant setting after surgery, and into combination with PRMT5 inhibitors, immunotherapy, and antibody-drug conjugates.
Grateful to David for the conversation, and to every patient who’s trusted us with a clinical trial to get us here.
Watch New breakthroughs in pancreatic cancer treatment and research.”
You can also read:
Targeting the Primary Tumor in Metastatic Pancreatic Cancer 2026
